Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Preston Peterson

Nurse Practitioner, Gerontology Reno, NV Nurse Practitioner

NPI 1801453030 CMS profile 10699147

1500 E 2Nd St Ste 100, Reno, NV 89502

Open in the dashboard

General payments

$3,458

91 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Preston Peterson of Reno, NV is reported in the CMS Open Payments database as having received $3,458 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $773 23
2024 General $2,180 45
2023 General $417 18
2022 General $59 3
2021 General $29 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Preston Peterson
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Preston Peterson were reported at $773. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Preston Peterson Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $29 $133 $44–$396 $132
2022 $59 $142 $48–$452 $149
2023 $417 $158 $53–$482 $160
2024 $2,180 $171 $55–$533 $164
2025 $773 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Atricure, Inc. $1,301 11 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $312 7 payments
  3. Edwards Lifesciences Corporation $283 5 payments
  4. Pfizer Inc. $166 9 payments
  5. Novartis Pharmaceuticals Corporation $163 6 payments
  6. Janssen Pharmaceuticals, Inc $107 6 payments
  7. Alnylam Pharmaceuticals Inc. $106 4 payments
  8. Medtronic, Inc. $106 2 payments
  9. HeartFlow, Inc. $98 2 payments
  10. Lexicon Pharmaceuticals, Inc. $80 4 payments
  11. Other $735 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,624 88 payments
  2. Travel and Lodging $816 2 payments
  3. Education $18 1 payment
Products named General payments · program years 2021–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,192 6 payments
  2. SYNERGY ABLATION SYSTEM $735 5 payments
  3. LifeVest $312 7 payments
  4. LEQVIO $163 6 payments
  5. SAPIEN 3 Ultra RESILIA $160 4 payments
  6. ELIQUIS $150 8 payments
  7. PASCAL $123 1 payment
  8. ATRICLIP LAA EXCLUSION SYSTEM $110 5 payments
  9. AMVUTTRA $106 4 payments
  10. FFRct $98 2 payments
  11. Other $1,141 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,514

Median for Nurse Practitioner: 389

Drug cost

$405,469

Median for Nurse Practitioner: $21,885

Branded share of claims

29.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 143 $138,458
Entresto Sacubitril/Valsartan Brand 100 $115,970
Jardiance Empagliflozin Brand 50 $72,232
Xarelto Rivaroxaban Brand 36 $44,413
Farxiga Dapagliflozin Propanediol Brand 16 $17,450
Metoprolol Succinate Generic 199 $2,300
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 41 $1,809
Atorvastatin Calcium Generic 96 $1,656
Flecainide Acetate Generic 27 $1,482
Losartan Potassium Generic 87 $1,213

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$52,985

Medicare's payments for the services billed

Medicare patients

406

Average age 77

Services billed

831

194 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 44%
Atrial fibrillation 43%
Diabetes 31%
Heart failure 30%
Chronic kidney disease 25%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record